Acute Myeloid and Myelodysplastic Disorders
Curis Inc. is active in acute myeloid leukemia and higher-risk myelodysplastic syndrome, with research centered on relapsed and refractory disease settings and molecularly defined subgroups.
- Relapsed or refractory AML
- Higher-risk MDS
- FLT3-mutated AML
- Spliceosome-mutated myeloid disease
The sponsor’s work in this area includes hematologic malignancies with a focus on difficult-to-treat myeloid cancers.
Primary Central Nervous System Lymphoma
Another major interest is primary central nervous system lymphoma, including relapsed or refractory disease and treatment combinations evaluated in patients with limited therapeutic options.
- R/R PCNSL
- Anti-cancer activity in CNS lymphoma
- Combination therapy in lymphoma
This area reflects a strong therapeutic focus on lymphoma involving the central nervous system.
Chronic Lymphocytic Leukemia and B-cell Malignancies
Curis Inc. also funds research in chronic lymphocytic leukemia and related B-cell malignancies, with attention to patients whose disease has returned or no longer responds to treatment.
- CLL
- Other B-cell malignancies
- Relapsed or refractory lymphoid cancers
These studies extend the sponsor’s oncology portfolio across lymphoid neoplasms and other blood cancers.
Targeted Hematologic Oncology
The sponsor’s clinical research includes targeted treatment approaches for hematologic malignancies, with interest in combinations involving BTK inhibition and IRAK4 inhibition.
- Targeted therapy combinations
- Relapsed or refractory blood cancers
- Mechanism-based oncology research
These programs connect molecularly targeted oncology with disease-specific development in leukemia and lymphoma.
Supportive Clinical Pharmacology
Curis Inc. also supports clinical research in pharmacokinetics and treatment administration considerations, including studies in healthy volunteers that inform the clinical use of its oncology candidates.
- Pharmacokinetic assessment
- Oral oncology agents
- Clinical development support
This area complements the sponsor’s broader focus on cancer therapeutics and drug development.
